Basal Cell Carcinoma Of Skin — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for basal cell carcinoma of skin. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
2
Active US patents
49/100
Avg vulnerability
—
Annual revenue covered

Originators in Basal Cell Carcinoma Of Skin

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Roche 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating basal cell carcinoma of skin. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Erivedge
vismodegib
 Roche 2 49 — 2028-11-11

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9278961 Erivedge method of use 75 2028-12-15
7888364 Erivedge composition of matter 22 2028-11-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7888364 Erivedge composition of matter 22 2028-11-11
9278961 Erivedge method of use 75 2028-12-15

Related